ATE447010T2 - Verfahren zur produktion von viralen antigenen im grossmassstab - Google Patents

Verfahren zur produktion von viralen antigenen im grossmassstab Download PDF

Info

Publication number
ATE447010T2
ATE447010T2 AT02792957T AT02792957T ATE447010T2 AT E447010 T2 ATE447010 T2 AT E447010T2 AT 02792957 T AT02792957 T AT 02792957T AT 02792957 T AT02792957 T AT 02792957T AT E447010 T2 ATE447010 T2 AT E447010T2
Authority
AT
Austria
Prior art keywords
scale production
viral antigens
cell culture
directed
adherent cells
Prior art date
Application number
AT02792957T
Other languages
English (en)
Inventor
Manfred Reiter
Wolfgang Mundt
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21723079&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE447010(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Application granted granted Critical
Publication of ATE447010T2 publication Critical patent/ATE447010T2/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
AT02792957T 2001-12-10 2002-12-10 Verfahren zur produktion von viralen antigenen im grossmassstab ATE447010T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/006,881 US6951752B2 (en) 2001-12-10 2001-12-10 Method for large scale production of virus antigen
PCT/EP2002/014011 WO2003054174A1 (en) 2001-12-10 2002-12-10 Method for large scale production of virus antigen

Publications (1)

Publication Number Publication Date
ATE447010T2 true ATE447010T2 (de) 2009-11-15

Family

ID=21723079

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02792957T ATE447010T2 (de) 2001-12-10 2002-12-10 Verfahren zur produktion von viralen antigenen im grossmassstab

Country Status (17)

Country Link
US (2) US6951752B2 (de)
EP (3) EP2330189B1 (de)
JP (2) JP4370511B2 (de)
CN (2) CN100335619C (de)
AT (1) ATE447010T2 (de)
AU (1) AU2002358662B2 (de)
CA (1) CA2469644C (de)
DE (2) DE122010000025I1 (de)
DK (2) DK1453956T3 (de)
ES (2) ES2335395T5 (de)
FR (1) FR10C0026I1 (de)
HU (1) HU225791B1 (de)
MX (1) MXPA04005644A (de)
NO (1) NO20042910L (de)
PL (1) PL208232B1 (de)
RU (1) RU2314344C2 (de)
WO (1) WO2003054174A1 (de)

Families Citing this family (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7445924B2 (en) 2000-11-23 2008-11-04 Bavarian Nordic A/S Modified Vaccinia Ankara virus variant and cultivation method
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US7056723B2 (en) * 2001-12-20 2006-06-06 Bavarian Nordic A/S Method for the recovery and purification of poxviruses from infected cells
AU2003264144C1 (en) 2002-09-05 2009-12-17 Bavarian Nordic A/S Method for the cultivation of primary cells and for the amplification of viruses under serum free conditions
EP1575998A4 (de) * 2002-12-23 2007-07-25 Bristol Myers Squibb Co Verfahren zur kultivierung vonsäugetierzellen zur proteinproduktion
CA2551026A1 (en) * 2003-12-23 2005-07-14 Schering Corporation Methods for producing a549 cell lines stable in serum-free medium suspension culture
CN1922308A (zh) 2004-02-23 2007-02-28 克鲁塞尔荷兰公司 病毒纯化方法
JP4650798B2 (ja) * 2004-04-19 2011-03-16 デンカ生研株式会社 ウイルスの生産方法
AU2005245943A1 (en) * 2004-05-20 2005-12-01 Id Biomedical Corporation Process for the production of an influenza vaccine
US7344839B2 (en) * 2004-12-23 2008-03-18 Aurx, Inc. Virus preparations and methods
ES2526170T3 (es) * 2004-12-23 2015-01-07 Medimmune, Llc Línea celular MDCK no tumorigénica para propagar virus
JP2009532352A (ja) 2006-03-31 2009-09-10 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ワクチンのための高力価組み換えインフルエンザ・ウィルス
AU2007347716B2 (en) * 2006-09-15 2013-06-20 Medimmune, Llc MDCK cell lines supporting viral growth to high titers and bioreactor process using the same
JP5084214B2 (ja) * 2006-09-29 2012-11-28 一般財団法人日本ポリオ研究所 Ｉｐｖワクチン
EP2155863B1 (de) * 2007-05-04 2014-08-13 Baxter International Inc. Zweistufiges temperaturprofil für die propagierung von viren
US9474798B2 (en) 2007-06-18 2016-10-25 Wisconsin Alumni Research Foundation Influenza M2 protein mutant viruses as live influenza attenuated vaccines
JP2011512877A (ja) * 2008-03-12 2011-04-28 ワイス・エルエルシー 組換えタンパク質の大スケール産生に適した細胞を同定する方法
RU2011107757A (ru) 2008-08-01 2012-09-10 Гамма Ваксинс Пти Лимитед (Au) Вакцины против гриппа
CN102216450B (zh) * 2008-09-24 2014-05-14 米迪缪尼有限公司 培养细胞、增殖和纯化病毒的方法
KR20110074563A (ko) 2008-09-24 2011-06-30 메디뮨 엘엘씨 바이러스의 정제 방법
ES2524975T3 (es) 2009-07-31 2014-12-16 Ge Healthcare Bio-Sciences Corp. Cepa del virus de la fiebre amarilla de alto rendimiento con mayor propagación en células
JP2013507990A (ja) 2009-10-26 2013-03-07 ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス
WO2011077035A1 (fr) * 2009-12-23 2011-06-30 Sanofi Pasteur Procede de culture de cellules adherentes
US10130697B2 (en) 2010-03-23 2018-11-20 Wisconsin Alumni Research Foundation (Warf) Vaccines comprising mutant attenuated influenza viruses
SG184833A1 (en) 2010-04-14 2012-11-29 Emd Millipore Corp Methods of producing high titer, high purity virus stocks and methods of use thereof
US9725689B2 (en) 2010-10-08 2017-08-08 Terumo Bct, Inc. Configurable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system
CN101979517B (zh) * 2010-10-15 2011-12-28 普莱柯生物工程股份有限公司 一种利用生物反应器大规模生产流感病毒的方法
WO2012100302A1 (en) 2011-01-27 2012-08-02 Gamma Vaccines Pty Limited Combination vaccines
ES2655051T3 (es) 2011-08-26 2018-02-16 Wisconsin Alumni Research Foundation Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas
CN102492659A (zh) * 2011-11-14 2012-06-13 成都康华生物制品有限公司 一种疫苗生产用甲肝病毒的生产方法
JP2016524915A (ja) 2013-07-15 2016-08-22 ウィスコンシン アルムニ リサーチ ファンデイション Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス
CN103387958B (zh) * 2013-08-16 2016-04-06 北京科兴中维生物技术有限公司 人胚肺成纤维细胞sv-7在病毒培养中的应用
EP3068867B1 (de) 2013-11-16 2018-04-18 Terumo BCT, Inc. Zellenexpansion in einem bioreaktor
US11008547B2 (en) 2014-03-25 2021-05-18 Terumo Bct, Inc. Passive replacement of media
US10053671B2 (en) 2014-06-20 2018-08-21 Wisconsin Alumni Research Foundation (Warf) Mutations that confer genetic stability to additional genes in influenza viruses
EP3198006B1 (de) 2014-09-26 2021-03-24 Terumo BCT, Inc. Geplante fütterung
SG11201706066RA (en) 2015-01-26 2017-08-30 Ube Industries Method of producing substance
SG11201705866XA (en) 2015-01-26 2017-08-30 Ube Industries Method, device and kit for mass cultivation of cells using polyimide porous membrane
US10633422B2 (en) 2015-06-01 2020-04-28 Wisconsin Alumni Research Foundation (Warf) Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
WO2017007839A1 (en) 2015-07-06 2017-01-12 Wisconsin Alumni Research Foundation (Warf) Improved influenza virus replication for vaccine development
JP2019510481A (ja) 2016-02-19 2019-04-18 ウィスコンシン アルムニ リサーチ ファンデイション ワクチン開発のための改善されたｂ型インフルエンザウイルス複製
WO2017205667A1 (en) 2016-05-25 2017-11-30 Terumo Bct, Inc. Cell expansion
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
KR102281173B1 (ko) 2016-07-25 2021-07-22 우베 고산 가부시키가이샤 사이펀식 배양법
WO2018021368A1 (ja) 2016-07-25 2018-02-01 宇部興産株式会社 細胞培養モジュール
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
JP7393945B2 (ja) 2017-03-31 2023-12-07 テルモ ビーシーティー、インコーポレーテッド 細胞増殖
WO2019084310A1 (en) 2017-10-25 2019-05-02 Yoshihiro Kawaoka HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION
US11612648B2 (en) * 2018-01-18 2023-03-28 Yisheng Biopharma (Singapore) Pte Ltd Method for adapting influenza viruses to Vero cells
EP3749757A4 (de) * 2018-02-07 2021-11-24 Bharat Biotech International Limited Verfahren zur enterovirusreinigung und -inaktivierung und daraus erhaltene impfstoffzusammensetzungen
US12343390B2 (en) 2018-08-07 2025-07-01 Wisconsin Alumni Research Foundation (Warf) Recombinant biologically contained filovirus vaccine
US11389523B2 (en) 2018-08-20 2022-07-19 Wisconsin Alumni Research Foundation (Warf) Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein
EP3914295A2 (de) 2019-01-23 2021-12-01 Yoshihiro Kawaoka Mutationen zur verleihung von genetischer stabilität gegenüber zusätzlichen genen bei grippeviren
WO2020153619A1 (ko) * 2019-01-25 2020-07-30 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
KR102228267B1 (ko) * 2019-01-25 2021-03-17 바이로큐어 주식회사 Bhk-21 세포를 이용한 바이러스 생산방법
WO2020163804A1 (en) 2019-02-08 2020-08-13 Wisconsin Alumni Research Foundation (Warf) Humanized cell line
CN113423825A (zh) * 2019-02-15 2021-09-21 科学生物技术公司 病毒生产方法
CN114929269A (zh) 2019-05-01 2022-08-19 威斯康星校友研究基金会(Warf) 用于疫苗开发的改进的流感病毒复制
CA3144960A1 (en) * 2019-07-01 2021-01-07 Ology Bioservices, Inc. Method for cultivation of adherent cells in a multiparallel bioreactor
TWI917330B (zh) 2019-08-09 2026-03-11 日商Ｕｂｅ股份有限公司 胞外體的產生方法
TW202122569A (zh) 2019-08-09 2021-06-16 日商宇部興產股份有限公司 應用小片多孔膜的細胞培養法
WO2021041624A2 (en) 2019-08-27 2021-03-04 Yoshihiro Kawaoka Recombinant influenza viruses with stabilized ha for replication in eggs
JP2023511444A (ja) 2020-01-24 2023-03-17 ウィスコンシン アルムニ リサーチ ファンデイション 安定化されたｎａを有する組換えインフルエンザウイルス
WO2021195410A1 (en) 2020-03-25 2021-09-30 Wisconsin Alumni Research Foundation (Warf) Recombinant multivalent influenza viruses
CN111850169B (zh) * 2020-07-16 2022-09-27 华农（肇庆）生物产业技术研究院有限公司 一种计算AIV在MDCK-sus细胞中细胞单位均产毒量的方法
EP4314244B1 (de) 2021-03-23 2025-07-23 Terumo BCT, Inc. Zellerfassung und -erweiterung
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4525349A (en) 1981-12-29 1985-06-25 Societe Anonyme Dite: Institut Merueux Process for the large-scale production of a vaccine against poliomyelitis and the resulting vaccine
US5719051A (en) * 1989-12-22 1998-02-17 Immuno Aktiengesellschaft Perfusion system and a method for the large scale production of virus or virus antigen
AT393356B (de) 1989-12-22 1991-10-10 Immuno Ag Verfahren zur herstellung von fsme-virus-antigen
FR2723740B1 (fr) 1994-08-16 1996-11-08 Pasteur Merieux Serums Vacc Procede de preparation d'antigenes du virus grippal, antigenes obtenus et leurs applications
US5824536A (en) * 1994-08-23 1998-10-20 St. Jude Children's Research Hospital Influenza virus replicated in mammalian cell culture and vaccine production
ATE542891T1 (de) 1994-11-10 2012-02-15 Baxter Healthcare Sa Verfahren zur herstellung von biologischen produkten in protein-freier kultur
DE19612966B4 (de) * 1996-04-01 2009-12-10 Novartis Vaccines And Diagnostics Gmbh & Co. Kg MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren
GB2319413B (en) * 1996-11-12 2001-06-06 Lsi Logic Corp Driver circuits
US6168944B1 (en) * 1997-01-31 2001-01-02 Schering Corporation Methods for cultivating cells and propagating viruses
IL131014A0 (en) * 1997-01-31 2001-01-28 Schering Plough Corp Methods for cultivating cells and propagating viruses
AT407255B (de) 1997-06-20 2001-02-26 Immuno Ag Rekombinanter zellklon mit erhöhter stabilität in serum- und proteinfreiem medium und verfahren zur gewinnung des stabilen zellklons
US5994134A (en) * 1998-05-04 1999-11-30 Canji, Inc. Viral production process
US6951752B2 (en) * 2001-12-10 2005-10-04 Bexter Healthcare S.A. Method for large scale production of virus antigen
US6855535B2 (en) * 2001-12-10 2005-02-15 Baxter Healthcare S.A. Method of large scale production of Hepatitis A virus

Also Published As

Publication number Publication date
EP1894998A1 (de) 2008-03-05
JP2009261410A (ja) 2009-11-12
PL208232B1 (pl) 2011-04-29
EP1453956B1 (de) 2009-10-28
ES2335395T5 (es) 2017-08-31
CN1617924A (zh) 2005-05-18
AU2002358662B2 (en) 2008-05-15
RU2004121178A (ru) 2005-10-10
US20030108860A1 (en) 2003-06-12
EP2330189A1 (de) 2011-06-08
NO20042910L (no) 2004-07-09
WO2003054174A1 (en) 2003-07-03
CN101100657B (zh) 2012-05-30
HUP0402415A2 (hu) 2005-02-28
DE60234211D1 (de) 2009-12-10
EP1453956A1 (de) 2004-09-08
JP5021000B2 (ja) 2012-09-05
DE122010000025I1 (de) 2010-08-12
DK1453956T3 (da) 2010-01-11
EP2330189B1 (de) 2014-05-21
US20050181495A1 (en) 2005-08-18
CA2469644A1 (en) 2003-07-03
HU225791B1 (en) 2007-09-28
ES2335395T3 (es) 2010-03-26
DK2330189T3 (da) 2014-06-16
AU2002358662A1 (en) 2003-07-09
EP1894998A8 (de) 2008-04-23
CN101100657A (zh) 2008-01-09
US7524676B2 (en) 2009-04-28
JP4370511B2 (ja) 2009-11-25
CA2469644C (en) 2013-07-23
ES2488818T3 (es) 2014-08-29
HUP0402415A3 (en) 2005-07-28
CN100335619C (zh) 2007-09-05
EP1453956B2 (de) 2017-01-18
RU2314344C2 (ru) 2008-01-10
PL373487A1 (en) 2005-09-05
HK1158691A1 (en) 2012-07-20
MXPA04005644A (es) 2005-04-19
JP2005512564A (ja) 2005-05-12
US6951752B2 (en) 2005-10-04
HK1115609A1 (en) 2008-12-05
FR10C0026I1 (fr) 2011-01-14
EP1453956B8 (de) 2010-02-10

Similar Documents

Publication Publication Date Title
DE60234211D1 (de) Verfahren zur produktion von viralen antigenen im grossmassstab
ATE414162T1 (de) Verfahren und materialien zur herstellung von glucosamin
ATE353370T1 (de) In vitro-rekonstitution von segmentierten, negativstrang-rna-viren
DK0414475T3 (da) Fremgangsmåder til dyrkning af HCV i B- eller T-lymfocyt-cellelinier
ATE474910T1 (de) L-glutaminsäure produzierender mikroorganismus sowie verfahren zur produktion von l- glutaminsäure
ATE426021T1 (de) Verfahren zur herstellung von biopterinen
DE59900442D1 (de) Solid-state-fermenter und verfahren zur solid-state-fermentation
ATE248793T1 (de) Verfahren zur umsetzung von sauerstoffverbindungen in olefinen in gegenwart von elektromagnetischer energie
WO2003067213A3 (en) Modulation of sulfate permease for photosynthetic hydrogen production
JP2005512564A5 (de)
DE69626022D1 (de) Verfahren zur industriellen herstellung eines japanischen enkephalitis impfstoffes, und so erhaltener impfstoff
ATE479743T1 (de) Verfahren zur herstellung von zellkulturen aus biologischen präparaten für chemotherapeutische und andere assays
ATE336567T1 (de) Zellkulturmedium
ATE553210T1 (de) Verfahren zur herstellung von l-threonin unter verwendung eines mikroorganismus mit inaktivierten galr gen.
ATE530657T1 (de) Verfahren zur herstellung von zellinien mit latentem immunschwächevirus
DE60118396D1 (de) Immobilisierungsträger mit einem porösen medium
ATE464375T1 (de) Verfahren zur herstellung von virusmaterial
EP1176194A4 (de) Verfahren der zellkultivierung
ATE423841T1 (de) Verwendung von glutaminfreien medium
ATE486124T1 (de) Keratinozyten-kulturverfahren und verwendung davon
DE60315261D1 (de) Verfahren zur herstellung von 5-formyl-valeronsäurenitril unter verwendung eines reaktivierten katalysators
ATE313622T1 (de) Verfahren zur züchtung von haftenden tierischen zellen
WO2002064811A3 (fr) Procede pour produire des proteines recombinantes, marquees par au moins un isotope
ATE321130T1 (de) Verfahren zur herstellung von hydroxynitril- lyasen
ATE521364T1 (de) Zusammensetzung und verfahren zur erhöhung der zelldichte in zellkulturen, die mit dem lentivirus infiziert sind